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Abstract
Background: Cardiac fibroblasts (CFs) are principal extracellular matrix-producing cells. In response 
to injury, CFs transdifferentiate into myofibroblasts. Intracellular calcium (Ca2+) signaling, involved in 
fibroblast proliferation and differentiation, is activated in fibroblasts through transient receptor potential 
(TRP) channels, but the function of these channels has not been investigated in human ventricular CFs. 
Under evaluation in this study, was the role of TRP channels in the differentiation of human ventricular 
CFs induced by transforming the growth factor beta (TGF-b), a pro-fibrotic cytokine.
Methods: Human ventricular CFs were used in this study. The differentiation of CFs into myofibro-
blast was induced with TGF-b and was identified by the expression of smooth muscle actin. 
Results: Results indicate that Ca2+ signaling was an essential component of ventricular CF dif-
ferentiation. CFs treated with TGF-b demonstrated increased expression of a TRP channel, TRPV4, 
both at the mRNA and protein levels, which corresponded with CF-myofibroblast trans-differentiation, 
as evidenced by the upregulation of a-smooth muscle actin, a myofibroblast marker, and plasminogen 
activator inhibitor-1, which are  fibrogenesis markers. An agonist of TRPV4 induced the conversion of 
CFs into myofibroblasts, whereas it’s antagonist as well a Ca2+ chelating agent reduced it, indicating 
that the Ca2+ influx throughTRPV4 is required for CF trans-differentiation. Overall, these results dem-
onstrate that TRPV4-mediated Ca2+ influx participates in regulating the differentiation of human 
ventricular CFs into myofibroblasts through the MAPK/ERK pathway.
Conclusions: Overall, these results demonstrate that TRPV4-mediated Ca2+ influx participates in 
regulating the differentiation of human ventricular CFs into myofibroblasts through the MAPK/ERK 
pathway. (Cardiol J 2020; 27, 2: 162–170)
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Introduction
Cardiac fibroblasts (CFs) residing in the inter-
stitial space comprise the largest cell population 
in the myocardium and provide structural support 
for cardiomyocytes by producing an extracellular 
matrix (ECM) which maintains heart architecture 
under physiological conditions [1]. CFs also play 
a key role in response to heart injury. Upon patho-
logical stimuli, CFs differentiate into myofibroblasts 
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characterized by contractility and overproduction of 
ECM, which causes wound retraction and healing 
by replacing necrotized cardiomyocytes. However, 
excessive activity of myofibroblasts can cause 
scarring and cardiac fibrosis followed by heart hy-
pertrophy, enlargement of cardiac chambers, cell 
apoptosis, and ultimately heart failure [2]. 
Myofibroblasts are absent in normal cardiac 
tissue and only appear following injury [3]. The dif-
ferentiation of CFs into myofibroblasts is a crucial 
process in heart remodeling, and it is established 
that the transforming growth factor (TGF)-b1 
secreted by inflammatory cells directly induces 
a switch from the quiescent phenotype of CFs to 
active synthetic and contractile phenotype of myo-
fibroblasts [4, 5]. The latter can be distinguished 
from CFs by the expression of several smooth 
muscle cell markers, including smooth muscle 
actin (a-SMA), which provide myofibroblast con-
tractility [6, 7].
Although a number of signaling pathways 
are known to mediate fibroblast-to-myofibroblast 
conversion and fibrogenesis in the heart, there are 
few effective therapies to treat cardiac fibrosis, 
emphasizing the need to identify new molecular 
targets. Ca2+ signals regulate diverse cellular func-
tions, and are known to be involved in fibroblast 
proliferation and ECM synthesis [8]. Fibroblasts 
have a relatively depolarized resting membrane 
potential, which is between –31 and –16 mV in 
atrial fibroblasts [9], and lack functional voltage-
gated Ca2+ channels [10]. Instead, they express 
transient receptor potential (TRP) channels which 
provide nonselective intracellular Ca2+ flux and are 
widely present in many cell types [11]. Recently 
four TRP channels; TRPM7, TRPC3, TRPC6, and 
TRPV4, were found to be essential for myofibro-
blast trans differentiation [12–15]. However, their 
function appears to be species- and tissue-specific 
and it is not known whether TRP-mediated Ca2+ 
signaling is specifically required for the conversion 
of human ventricular CFs into myofibroblasts [16]. 
Therefore, the aim of this study was to investigate 
the role of TRP channels in the TGF-b-mediated 
transformation of human ventricular CFs. 
Methods
Materials
Normal human ventricular cardiac fibro-
blasts (NHCF-V) (Product code; CC-2904) were 
purchased from Lonza (Walkersville Inc., MD, 
USA). An intracellular calcium chelator BAPTA-
AM, a selective antagonist (RN-9893), agonist 
(GSK1016790A) of TRPV4 and selective inhibitor 
of MAPK/ERK kinase (U0126) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) [17]. 
Polyclonal antibodies against TRPV4 were obtained 
from Alomone Labs (Jerusalem, Israel), plasmino-
gen activator inhibitor-1 (PAI-1)-specific antibody 
was from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA), a-SMA antibody was from Abcam 
(Cambridge, MA, USA), and monoclonal antibod-
ies against phosphorylated (p)-ERK and total ERK 
were obtained from Cell Signaling Technology 
(Danvers, MA, USA). TGF-b was purchased from 
PeproTech (Rocky Hill, NJ, USA).
Cell culture and TGF-b treatment
Cardiac fibroblasts were cultured in fibroblast 
growth medium (FGM, Lonza, Basel, Switzerland) 
supplemented with fetal calf serum (FCS), strep-
tomycin (50 μg/mL), and penicillin (100 U/mL) at 
37°C in a humidified atmosphere of 5% CO2. After 
24 h starvation in serum-free FGM, the medium 
was replaced by FGM containing 2 ng/mL re-
combinant human TGF-b. CFs were cultured for 
different times (0, 6, 12, 24, and 48 h). 
Polymerase chain reaction 
Gene-specific primers were used to detect the 
expression of human TRP channels as described 
previously [14]. Ventricular CFs were seeded into 
10-cm dishes, cultured in serum-free FGM for 
24 h, and then stimulated with TGF-b (2 ng/mL) 
for 3, 6, 12, 24, and 48 h. Cells were collected, and 
total RNA was extracted by Trizol (Invitrogen, 
Paisley, UK), and cDNA was synthesized, which 
was used as a template for the polymerase chain 
reaction (PCR). The amplified products were re-
solved by electrophoresis on 2% agarose gels and 
photographed using the FluorChem FC2 system 
(Cell Biosciences, Santa Clara, CA, USA).
Western blotting
Cardiac fibroblast differentiation was induced 
with 2 ng/mL TGF-b in the absence or presence 
of 1 μM/mL Ca2+ chelator BAPTA-AM for 48 h, 
or different concentrations of TRPV4 agonist 
GSK1016790A (10, 20 and 50 nM) or antagonist 
RN-9893 (10, 20, and 50 μM) for 24 h. DMSO 
was used as the vehicle control. For inhibition 
of ERK signaling, CFs were treated with U0126 
(10 μM), an inhibitor of MAPK/ERK kinase for 48 h. 
CFs were homogenized and lysed in RIPA buffer 
containing 50 mM Tris pH 7.4, 150 mM NaCl, 1% 
NP40, 0.5% sodium deoxycholate, 0.1% SDS, and 
protease inhibitor cocktail (Sigma, St. Louis, MO, 
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USA). Protein concentration in cell lysates was 
determined by the Bradford assay (Bio-Rad, Rich-
mond, CA, USA). Proteins were separated in 10% 
SDS-PAGE gels under reducing conditions, elec-
trophoretically transferred onto equilibrated poly-
vinylidene difluoride membranes (Immobilon-P, 
Millipore, Billerica, MA, USA), and probed with 
primary antibodies against TRPV4, a-SMA, 
p-ERK (T202/Y204), total ERK, PAI-1, and b-actin 
was used as an internal control. Reactivity to the 
anti-PAI-1 antibody was also determined in the cell 
culture supernatant. 
Measurement of cytosolic Ca2+
Ca2+ concentration was measured using a ra-
tiometric indicator Fura2 as described previously 
[18]. CFs were seeded onto black-walled 96-well 
plates (5 × 104 cells/well) and treated with 2 mM 
Ca2+ with or without TGF-b for 24 h to induce dif-
ferentiation into myofibroblasts. Cells were loaded 
with 5 µM Fura2/AM (Invitrogen, Carlsbad, CA, 
USA) in Krebs-Ringer bicarbonate buffer (126 mM 
NaCl, 4 mM KCl, 10 mM HEPES, 1 mM MgCl2, 
5.5 mM glucose, pH 7.4) for 30 min at 37°C, and 
fluorescence was measured at 510 nm in response 
to alternate excitation at 340 nm and 380 nm us-
ing a Flexstation fluorescence reader (Molecular 
Devices, Sunnyvale, CA, USA). The changes in 
the Fura2 fluorescence ratio (F340/F380) caused by 
2 mM Ca2+ were estimated by the area under the 
curve (AUC) and normalized to that caused by 
10 μM ionomycin-elicited Ca2+ signal. To assess 
the effects of TRPV4 activation, CFs were treated 
with 100 nM GSK1016790A. 
Statistical analysis
Statistical analysis was performed with  one-
way ANOVA followed by the Tukey post hoc analy-
sis or Student t-test; changes at p < 0.05 were 
considered statistically significant. All analyses 
were performed using SPSS v18 (SPSS, Chicago, 
IL, USA).
Results
TGF-b induces Ca2+-dependent  
differentiation of ventricular fibroblasts 
and expression of Ca2+-permeable  
channel TRPV4
To determine whether Ca2+ was required for 
TGF-b-mediated CF differentiation into myofibro-
blasts, TGF-b-stimulated cells were treated with 
the intracellular Ca2+ chelator BAPTA-AM and 
the expression of myofibroblast differentiation 
marker a-SMA (Fig. 1) was analyzed. The expres-
sion of a-SMA was suppressed with intracellular 
Ca2+ chelator. The results showed that chelation 
of intracellular Ca2+ inhibited CF differentiation, 
indicating that Ca2+ signaling was essential for CF 
conversion into myofibroblasts. 
To determine which Ca2+ channel is responsi-
ble for the TGF-b-induced differentiation of human 
ventricular CFs, the expression of TRP channels 
in CFs were examined. TRPV4 was the only TRP 
channel upregulated by TGF-b1 both at the mRNA 
(Fig. 2) and protein (Fig. 3) levels, which corre-
sponded to the induction of CF differentiation into 
myofibroblasts manifested by an increased expres-
sion of a-SMA and PAI-1 (Fig. 3). PAI-1 is the main 
inhibitor of serine proteases urinary and tissue 
plasminogen activators, which are responsible 
for plasmin formation, and of plasmin-dependent 
matrix metalloproteinases. Since plasmin and 
matrix metalloproteases degrade the ECM, their 
downregulation promotes ECM deposition; there-
fore, PAI-1 is considered a biomarker of excessive 
fibrogenesis and is implicated in the pathophysiol-
ogy of fibrosis [19]. 
TRPV4 is required for the differentiation  
of ventricular fibroblasts 
To determine the involvement of TRPV4 
in myofibroblast trans-differentiation, CFs were 
cultured with TRPV4 agonist GSK1016790A or 
antagonist RN-9893 and were then stimulated 
with TGF-b for 24 h. The results indicate that the 
TRPV4 agonist significantly promoted and TRPV4 
antagonist suppressed the conversion of CFs into 
myofibroblasts, as evidenced by dose-dependent 
increase and decrease, respectively, in a-SMA 
expression (Fig. 4). 
TRPV4 downstream signaling  
is mediated by ERK
The data obtained indicates that TRPV4 is 
involved in TGF-b-stimulated CF differentiation. 
Therefore, potential downstream signaling mecha-
nisms mediating TRPV4 activity were subse-
quently addressed. Since it is known that fibroblast 
differentiation is induced by reactive oxygen spe-
cies (ROS) and inhibited through mitogen-activated 
protein kinase (MAPK)/ERK signaling, and thus 
ERK1/2 phosphorylation in TGF-b-induced CFs 
treated with 1 μM of Ca2+ chelator BAPTA-AM was 
analyzed. ERK phosphorylation induced by TGF-b 
during the first hour of treatment was suppressed 
in a time-dependent manner by BAPTA-AM, which 
did not affect ERK activation at the early phase, but 
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inhibited it at the late phase (Fig. 1). Furthermore, 
ERK inhibitor U0126 caused the same effects as 
shown by TRPV4 antagonist RN-9893, since both 
these suppressed ERK phosphorylation as well as 
CF differentiation (Fig. 5). Overall, these results 
suggest the involvement of the MAPK/ERK path-
way in TGF-b-induced CF differentiation into myo-
fibroblasts. However, N-acetyl-L-cysteine (NAC), 
Figure 2. Transforming growth factor beta (TGF-b) induces TRPV4 mRNA expression. Cardiac fibroblasts were 
treated with 2 ng/mL TGF-b and analyzed for the expression of transient receptor potential (TRP) channels by 
a polymerase chain reaction (PCR); A. Representative image of an agarose gel showing PCR amplification products; 
B. Semi-quantitative analysis of TRPV4 mRNA expression relative to a-actin (*p < 0.05 vs. untreated cells).
Figure 1. Fibroblast differentiation depends on Ca2+. Cardiac fibroblasts induced with 2 ng/mL transforming growth 
factor beta (TGF-b) were treated or not with 1 μg/mL BAPTA-AM and analyzed for protein expression by Western 
blotting.
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Figure 3. Transforming growth factor beta (TGF-b) induces TRPV4 protein expression and differentiation of ven-
tricular fibroblasts. Cardiac fibroblasts were treated with 2 ng/mL TGF-b1 and analyzed for protein expression of 
TRPV4, smooth muscle actin alpha (a-SMA), and plasminogen activator inhibitor-1 (PAI-1) by Western blotting; 
A. Representative Western blotting image; B–D. Relative protein expression of TRPV (B), plasminogen activator in-
hibitor-1 (PAI-1) (C), and smooth muscle actin alpha (a-SMA) (D) after TGF-b treatment (*p < 0.05, **p < 0.01, and 
***p < 0.001, respectively, vs. untreated cells); con — control.
Figure 4. Transient receptor potential V4 (TRPV4) is involved in fibroblast differentiation. Cardiac fibroblasts (CFs) 
were pre-treated with the indicated concentrations of TRPV4 agonist GSK1016790A or antagonist RN-9893 and then 
treated with 2 ng/mL Transforming growth factor beta (TGF-b) for 24 h. CF conversion into myofibroblasts was as-
sessed based on smooth muscle actin alpha (a-SMA) expression analyzed by Western blotting.
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a well-known scavenger of ROS did not influence 
either ERK activation or CF differentiation (Fig. 5). 
TRPV4 is essential for Ca2+ entry into  
human ventricular fibroblasts
To analyze Ca2+ influx into differentiating CFs, 
cytosolic Ca2+ levels were measured using a ratio-
metric fluorescent dye Fura2. Intracellular Ca2+ 
concentration increased in CFs after treatment 
with the TRPV4 agonist as well as with TGF-b. 
Given that both TRPV4 and TGF-b induced CF 
differentiation, these results suggest that TRPV4 
as a Ca2+-permeable channel has a role in the differ-
entiation of human CFs into myofibroblasts (Fig. 6). 
Discussion
In the current study, the pathophysiological 
function of the Ca2+-permeable channel TRPV4 
in human ventricular CFs were under investiga-
tion. Results confirm that Ca2+ is essential for CF 
differentiation into myofibroblasts; most impor-
tantly, they also revealed that TGF-b upregulates 
TRPV4 expression and that TRPV4 mediates 
TGF-b-induced differentiation of human ventricular 
CFs into myofibroblasts via Ca2+-dependent ERK 
phosphorylation. 
Ca2+ signaling is a ubiquitous intracellular 
mechanism responsible for diverse cellular functions 
[8]. Several studies suggest that Ca2+ is essential 
for CF proliferation and differentiation. The mito-
genic effect of substance P in rat CFs was abolished 
by chelation of extracellular Ca2+ with EGTA, 
which inhibited cell proliferation [20]. Furthermore, 
a Ca2+ channel blocker prevented angiotensin 
II-mediated myocardial fibrosis and accumulation of 
myofibroblasts in vivo [21]. Consistent with these 
findings, the present results indicate that TGF-b-
-induced human ventricular CF differentiation into 
myofibroblasts was inhibited by intracellular Ca2+ 
chelation. Overall, these data prove that Ca2+ entry 
through Ca2+-permeable ion channels are important 
for fibroblast gene expression and differentiation.
Fibroblasts are electrically non-excitable cells 
and have high membrane resistance and a rela-
tively depolarized resting membrane potential of 
Figure 5. ERK activation is involved in TRPV4-mediated differentiation of human ventricular fibroblasts. Cardiac 
fibroblasts (CFs) were treated with 2 ng/mL of transforming growth factor beta (TGF-b) in the presence or absence 
of selective ERK inhibitor U0126 (10 μM), reactive oxygen species scavenger N-acetyl-L-cysteine (NAC 0.5 mM), or 
TRPV4 antagonist RN-9893 (50 μM) and analyzed for the expression of p-ERK (T202/Y204) and smooth muscle actin 
alpha (a-SMA).
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–15.9 ± 2.1 mV [22]. CFs typically do not express 
voltage-gated Ca2+ channels including those of 
L-type characteristic for cardiomyocytes [23] and 
are known to be mechanosensitive [10]. Therefore, 
CFs need a different Ca2+-signaling pathway to 
facilitate differentiation into myofibroblasts. The 
TRP superfamily of ion channels comprises non-
selective cation channels permeable for Ca2+ and 
Mg2+. There are 28 mammalian TRP genes divided 
into six subfamilies based on amino acid homol-
ogy: TRPC (Canonical), TRPV (Vanilloid), TRPM 
(Melastatin), TRPA (Ankyrin), TRPP (Polycystin), 
and TRPML (Mucolipin). Among these, all TRPC 
and TRPV channels as well as TRPM1, 2, 3, 6, 7, 
and 8, TRPA1, TRPP2, 3, and 5, and TRPML1, 2, 
and 3 are permeable for Ca2+ [24]. Several previous 
studies indicate that TRP channels are involved in 
Ca2+-dependent regulation of CF differentiation 
into myofibroblasts in different mammalian species. 
Thus, Du et al. [14] suggested that TRPM7 played 
a major role in Ca2+ entry into human atrial fibro-
blasts by showing that the expression of TRPM7 
mRNA was increased by TGF-b which required 
a TRPM7-mediated Ca2+ signal for its effect on CF 
proliferation and differentiation. Other investiga-
tors showed that the proliferation and differentia-
tion of rat CFs is regulated by Ca2+ influx through 
TRPC3 [15], whereas TRPC6 was necessary for 
the transformation of mouse embryonic CFs into 
myofibroblasts [13]. Furthermore, it has been 
demonstrated that a mechanosensitve channel 
TRPV4 is required for TGF-b-induced differen-
tiation of adult rat CFs into myofibroblasts and 
that TGF-b upregulated TRPV4 expression and 
TRPV4-mediated Ca2+ influx [12]. These findings 
indicate that TRP channels regulate CF differen-
tiation into myofibroblasts, but their activity is 
species-and tissue-specific. The present study is 
the first to investigate the role of TRP channels 
in human ventricular CFs and the obtained results 
indicate that TRPV4 is the channel involved in 
TGF-b-induced conversion of human ventricular 
CFs into myofibroblasts. TRPV4 expression was 
upregulated by TGF-b both at the mRNA and 
protein levels, which correlated with the induc-
tion of Ca2+ influx as well as myofibroblast trans-
differentiation. At the same time, TRPV4 inhibi-
tion suppressed, while its activation induced the 
differentiation of CFs, confirming the regulatory 
role of TRPV4 in the process.
Transient receptor potential channels be-
longing to different subfamilies induce distinct 
downstream signaling mechanisms. TRPC6 was 
shown to upregulate Ca2+-responsive protein 
phosphatase calcineurin through its downstream 
transcriptional effector, nuclear factor of activated 
T-cells (NFAT), which resulted in myofibroblast 
trans-differentiation, whereas TRPC6 expression 
was induced by TGF-b through the MAPK/p38 
pathway [13]. It has been suggested that TRPC3 
expression mediating CF differentiation could be 
via a potential downstream mechanism involving 
the activation of ERK1/2 [15]. Protein kinases 
ERK1/2 are key intracellular signaling molecules 
regulated by phosphorylation and implicated in nu-
merous biological processes, including cell growth, 
Figure 6. TRPV4 mediates Ca2+ influx required for cardiac fibroblasts (CFs) differentiation; A. Ca2+ influx was elicited by 
2 mM Ca2+ and further augmented by the treatment with TRPV4 agonist GSK1016790A; B. Ca2+ influx was compared 
between control CFs (clear bar) and transforming growth factor beta (TGF-b)-treated CFs (gray bar); the treatment 
with TRPV4 agonist GSK1016790A further increased Ca2+ influx (*p < 0.05 vs. control).
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survival, and differentiation. In the current study, 
CF differentiation and ERK1/2 phosphorylation 
were increased by TGF-b, but were decreased by 
the intracellular Ca2+ chelator, TRPV4 antagonist, 
and ERK inhibitor, indicating the involvement of 
ERK1/2 in TRPV4-dependent conversion of ven-
tricular CFs into myofibroblasts. 
Based on the current findings, the following 
mechanism underlying fibroblast trans-differen-
tiation in the ventricle can be suggested: TGF-b 
secreted by inflammatory cells after heart injury 
upregulates the expression of TRPV4 and Ca2+ influx, 
which activates the MAPK/ERK pathway and down-
stream transcription of the genes encoding myofibro-
blast markers such as a-SMA, leading to a phenotypic 
switch from CFs to myofibroblasts (Fig. 7).
Conclusions
In conclusion, it was demonstrated that the 
Ca2+-permeable cation channel TRPV4 participated 
in Ca2+-mediated signaling in human ventricular 
fibroblasts, promoting their differentiation into 
myofibroblasts through the MAPK/ERK pathway. 
Findings herein, indicate that TRPV4 plays an 
important biological role in the regulation of left 
ventricular function and fibrogenesis in the heart, 
suggesting TRPV4 as a potential molecular target 
to attenuate cardiac fibrosis.
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